IRIS Accounts Production v26.1.0.640 01947122 director 31.7.24 30.7.25 30.7.25 false true false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 01947122 2024-07-30 01947122 2025-07-30 01947122 2024-07-31 2025-07-30 01947122 2023-07-31 01947122 2023-08-01 2024-07-30 01947122 2024-07-30 01947122 ns15:EnglandWales 2024-07-31 2025-07-30 01947122 ns14:PoundSterling 2024-07-31 2025-07-30 01947122 ns10:Director1 2024-07-31 2025-07-30 01947122 ns10:PrivateLimitedCompanyLtd 2024-07-31 2025-07-30 01947122 ns10:SmallEntities 2024-07-31 2025-07-30 01947122 ns10:AuditExempt-NoAccountantsReport 2024-07-31 2025-07-30 01947122 ns10:SmallCompaniesRegimeForDirectorsReport 2024-07-31 2025-07-30 01947122 ns10:SmallCompaniesRegimeForAccounts 2024-07-31 2025-07-30 01947122 ns10:FullAccounts 2024-07-31 2025-07-30 01947122 ns10:RegisteredOffice 2024-07-31 2025-07-30 01947122 ns5:CurrentFinancialInstruments 2025-07-30 01947122 ns5:CurrentFinancialInstruments 2024-07-30 01947122 ns5:Non-currentFinancialInstruments 2025-07-30 01947122 ns5:Non-currentFinancialInstruments 2024-07-30 01947122 ns5:ShareCapital 2025-07-30 01947122 ns5:ShareCapital 2024-07-30 01947122 ns5:RetainedEarningsAccumulatedLosses 2025-07-30 01947122 ns5:RetainedEarningsAccumulatedLosses 2024-07-30 01947122 ns5:PlantMachinery 2024-07-31 2025-07-30 01947122 ns5:MotorVehicles 2024-07-31 2025-07-30 01947122 ns5:ComputerEquipment 2024-07-31 2025-07-30 01947122 ns5:LandBuildings 2024-07-30 01947122 ns5:PlantMachinery 2024-07-30 01947122 ns5:MotorVehicles 2024-07-30 01947122 ns5:ComputerEquipment 2024-07-30 01947122 ns5:LandBuildings 2024-07-31 2025-07-30 01947122 ns5:LandBuildings 2025-07-30 01947122 ns5:PlantMachinery 2025-07-30 01947122 ns5:MotorVehicles 2025-07-30 01947122 ns5:ComputerEquipment 2025-07-30 01947122 ns5:LandBuildings 2024-07-30 01947122 ns5:PlantMachinery 2024-07-30 01947122 ns5:MotorVehicles 2024-07-30 01947122 ns5:ComputerEquipment 2024-07-30 01947122 ns5:LeasedAssetsHeldAsLessee ns5:MotorVehicles 2024-07-31 2025-07-30 01947122 ns5:LeasedAssetsHeldAsLessee ns5:MotorVehicles 2025-07-30 01947122 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-07-30 01947122 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-07-30 01947122 ns5:DeferredTaxation 2024-07-31 2025-07-30 01947122 ns5:DeferredTaxation 2025-07-30

REGISTERED NUMBER: 01947122 (England and Wales)

| SHEPHERDS SPRING PHARMACY LIMITED |

| UNAUDITED FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 30 JULY 2025 |

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JULY 2025

Page |

Company Information | 1 |

Balance Sheet | 2 |

Notes to the Financial Statements | 4 |

SHEPHERDS SPRING PHARMACY LIMITED

COMPANY INFORMATION

FOR THE YEAR ENDED 30 JULY 2025

| DIRECTOR: | Mrs J K Sembhi

| REGISTERED OFFICE: | 121 Henley Road

| Ilford

| Essex

| IG1 2TS

| REGISTERED NUMBER: | 01947122 (England and Wales)

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

BALANCE SHEET

30 JULY 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 38,211 |  | 5,087 |  |

CURRENT ASSETS

Stocks | 5 | 50,000 |  | 45,000 |  |

Debtors | 6 | 815,825 |  | 490,159 |  |

Cash at bank and in hand | 165,043 |  | 233,253 |  |

1,030,868 |  | 768,412 |  |

CREDITORS

Amounts falling due within one year | 7 | 395,639 |  | 330,174 |  |

NET CURRENT ASSETS | 635,229 |  | 438,238 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 673,440 |  | 443,325 |  |

CREDITORS

Amounts falling due after more than one year | 8 | (32,456 | ) | - |  |

PROVISIONS FOR LIABILITIES | 10 | (9,560 | ) | - |  |

NET ASSETS | 631,424 |  | 443,325 |  |

CAPITAL AND RESERVES

Called up share capital | 2 |  | 2 |  |

Retained earnings | 631,422 |  | 443,323 |  |

SHAREHOLDERS' FUNDS | 631,424 |  | 443,325 |  |

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

BALANCE SHEET - continued

30 JULY 2025

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 July 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 July 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 20 April 2026 and were signed by:

Mrs J K Sembhi - Director

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JULY 2025

1. | STATUTORY INFORMATION

| Shepherds Spring Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Going concern

| The financial statements have been prepared on a going concern basis which assumes that the company will continue in operational existence for the foreseeable future. In making their assessment, the director has reviewed the balance sheet, the likely future cashflows of the business and have considered the facilities that are available to the company along with their continued support.

| At the date of approving the financial statements the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and that the going concern basis of accounting remains appropriate. The director continues to adopt the going concern basis of accounting in preparing the financial statements.

| Significant judgements and estimates

| In the application of the company's accounting policies, which are described in note 2, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

| The estimates and underlying assumptions are reviewed on a ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

| Turnover

| Turnover is measured at fair value of the consideration received or receivable net of VAT and discounts. The policies adopted for the recognition of turnover are as follows:-

| Revenue represents retail sales to customers and is measured at fair value of the consideration received or receivable and is recognised when all risk and rewards of ownership are transferred to the end customer.

| NHS income is recognised in the period which it is due.

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JULY 2025

2. | ACCOUNTING POLICIES - continued

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.

| Plant and machinery | - | 15% on reducing balance

| Motor vehicles | - | 25% on reducing balance

| Computer equipment | - | 33% on cost

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Hire purchase and leasing commitments

| Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

| The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JULY 2025

2. | ACCOUNTING POLICIES - continued

| Cash and cash equivalents

| Cash and cash equivalents are basic financial instruments and include cash in hand and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

| Financial instruments

| The company has elected to apply the provisions of Section 11 "Basic Financial Instruments".

| Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realize the asset and settle the liability simultaneously.

| Basic financial assets

| Basic financial assets, which include trade and other debtors, loans to related companies and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortized cost using the effective interest method unless the arrangement constitutes a financing transaction, where the financial asset is measured at the present value of the future receipts discounted at a market rate of interest.

| Basic financial liabilities

| Basic financial liabilities, including trade and other creditors, loans to related companies and bank loans are initially recognised at transaction price unless the arrangement constitutes a financial transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest.

| Impairment

| Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the assets cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit and loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

| Provisions

| Provisions are recognised when the company has an obligation at the balance sheet date as a result of a past event, it is probable that an outflow of economic benefit will be required in settlement and the amount can be reliably estimated.

| Where there are a number of similar obligations, the likelihood that an outflow of economic benefits will be required in settlement is determined by considering the class of obligation as a whole. A provision is recognised even if the likelihood of an outflow with respect of any one item in the same class of obligations may be small.

| Provisions are not made for future operating losses.

| Provisions are measures at the present value of the cost expected to be required to settle the obligation using a pre-tax rate that reflects current market assessment of the time value of money and the risks specific to the obligation. The increase in the provision due to the passing of time is recognised as a cost in the income statement.

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JULY 2025

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 9 (2024 - 9 ) .

4. | TANGIBLE FIXED ASSETS

| Freehold |  | Plant and |  | Motor |  | Computer |

| property |  | machinery |  | vehicles |  | equipment |  | Totals

£ | £ | £ | £ | £ |

| COST

| At 31 July 2024 | 30,287 |  | 34,698 |  | - |  | 5,679 |  | 70,664 |  |

| Additions | - |  | - |  | 43,250 |  | - |  | 43,250 |  |

| At 30 July 2025 | 30,287 |  | 34,698 |  | 43,250 |  | 5,679 |  | 113,914 |  |

| DEPRECIATION

| At 31 July 2024 | 30,287 |  | 34,454 |  | - |  | 836 |  | 65,577 |  |

| Charge for year | - |  | 49 |  | 8,203 |  | 1,874 |  | 10,126 |  |

| At 30 July 2025 | 30,287 |  | 34,503 |  | 8,203 |  | 2,710 |  | 75,703 |  |

| NET BOOK VALUE

| At 30 July 2025 | - |  | 195 |  | 35,047 |  | 2,969 |  | 38,211 |  |

| At 30 July 2024 | - |  | 244 |  | - |  | 4,843 |  | 5,087 |  |

| Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

| Motor

| vehicles

£ |

| COST

| Additions | 43,250 |  |

| At 30 July 2025 | 43,250 |  |

| DEPRECIATION

| Charge for year | 8,203 |  |

| At 30 July 2025 | 8,203 |  |

| NET BOOK VALUE

| At 30 July 2025 | 35,047 |  |

5. | STOCKS

2025 | 2024 |

£ | £ |

| Stocks | 50,000 |  | 45,000 |  |

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JULY 2025

6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 133,892 |  | 158,776 |  |

| Amounts owed by group undertakings | 377,604 |  | - |  |

| Amounts owed by participating interests | 260,029 |  | 290,407 |  |

| VAT | 39,560 |  | 39,049 |  |

| Prepayments | 4,740 |  | 1,927 |  |

815,825 |  | 490,159 |  |

7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Hire purchase contracts | 5,888 |  | - |  |

| Trade creditors | 226,431 |  | 226,164 |  |

| Amounts owed to group undertakings | 529 |  | - |  |

| Amounts owed to participating interests | 97,421 |  | 12,146 |  |

| Corporation tax | 15,842 |  | 47,667 |  |

| Social security and other taxes | 14,383 |  | 24,596 |  |

| Other creditors | 981 |  | 286 |  |

| Accrued expenses | 34,164 |  | 19,315 |  |

395,639 |  | 330,174 |  |

8. | CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR |

2025 | 2024 |

£ | £ |

| Hire purchase contracts | 32,456 |  | - |  |

9. | SECURED DEBTS

| The company's bankers, Santander UK PLC, have taken a fixed and floating charge over the assets owned by the company.

10. | PROVISIONS FOR LIABILITIES

2025 | 2024 |

£ | £ |

| Deferred tax | 9,560 |  | - |  |

| Deferred |

| tax |

£ |

| Provided during year | 9,560 |  |

| Balance at 30 July 2025 | 9,560 |  |

SHEPHERDS SPRING PHARMACY LIMITED (REGISTERED NUMBER: 01947122)

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30 JULY 2025

11. | RELATED PARTY DISCLOSURES

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| Sach Chemist Ltd is a related company through common directorship and shareholdings. At 30 July 2025, the company owed £97,421 (2024: £12,146) to Sach Chemist Ltd.

| Pharmex Limited is a related company through common directorship and shareholdings. At 30 July 2025, the company owed £529 (2024: £nil) to Pharmex Limited.

| GS Health Ltd is a related company through common directorship and shareholdings. At 30 July 2025, the company was owed £250,059 (2024 :£280,437) by GS Health Ltd.

| Acorns Pharmaceuticals Ltd is a related company through common directorship and shareholdings. At 30 July 2025, the company was owed £9,970 (2024: £9,970) by Acorns Pharmaceuticals Ltd.

| All above related balances are interest free and are repayable upon demand.

12. | ULTIMATE CONTROLLING PARTY

| The ultimate controlling party of the company is Pharmex Holdings Limited, the ultimate parent company, a company registered in England and Wales.